Nevro Corp (NASDAQ:NVRO) CEO Rami Elghandour sold 3,000 shares of the company’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $100.00, for a total value of $300,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Nevro Corp (NASDAQ:NVRO) opened at 99.07 on Friday. The company’s 50-day moving average price is $97.77 and its 200-day moving average price is $79.64. The stock’s market cap is $2.82 billion. Nevro Corp has a 1-year low of $36.51 and a 1-year high of $106.93.
Nevro Corp (NASDAQ:NVRO) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.16. The company had revenue of $55.40 million for the quarter, compared to analyst estimates of $45.11 million. The business’s revenue was up 385.5% compared to the same quarter last year. Analysts predict that Nevro Corp will post ($1.42) EPS for the current year.
A number of research analysts have recently commented on NVRO shares. Zacks Investment Research upgraded Nevro Corp from a “hold” rating to a “buy” rating and set a $110.00 price objective on the stock in a report on Wednesday, October 5th. B. Riley started coverage on Nevro Corp in a report on Wednesday, September 21st. They issued a “buy” rating and a $114.00 price objective on the stock. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $112.00 price objective (up previously from $98.00) on shares of Nevro Corp in a report on Thursday, August 11th. JPMorgan Chase & Co. increased their price objective on Nevro Corp from $84.00 to $100.00 and gave the company an “overweight” rating in a report on Tuesday, August 9th. Finally, JMP Securities increased their price objective on Nevro Corp from $90.00 to $110.00 and gave the company a “market outperform” rating in a report on Tuesday, August 9th. Eleven investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $104.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Creative Planning boosted its position in shares of Nevro Corp by 1,179.5% in the third quarter. Creative Planning now owns 2,495 shares of the company’s stock worth $260,000 after buying an additional 2,300 shares in the last quarter. First Mercantile Trust Co. boosted its position in shares of Nevro Corp by 1.2% in the third quarter. First Mercantile Trust Co. now owns 13,500 shares of the company’s stock worth $1,409,000 after buying an additional 165 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Nevro Corp by 110.8% in the third quarter. BNP Paribas Arbitrage SA now owns 1,977 shares of the company’s stock worth $206,000 after buying an additional 1,039 shares in the last quarter. Macquarie Group Ltd. bought a new position in shares of Nevro Corp during the second quarter worth approximately $6,145,000. Finally, Nomura Holdings Inc. bought a new position in shares of Nevro Corp during the second quarter worth approximately $388,000.
Nevro Corp Company Profile
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Receive News & Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related companies with MarketBeat.com's FREE daily email newsletter.